Zollinger‑Ellison syndrome (gastrinoma) - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Zollinger‑Ellison Syndrome (Gastrinoma) – Complete Medical Guide

Zollinger‑Ellison Syndrome (Gastrinoma)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more tumors called gastrinomas produce excessive amounts of the hormone gastrin. Elevated gastrin stimulates the stomach to secrete large volumes of acid, leading to severe peptic ulcer disease, gastro‑esophageal reflux, and malabsorption.

  • Incidence: Approximately 0.5–2 cases per million people per year.[1]
  • Prevalence: About 1–3 per 100,000 individuals worldwide.[2]
  • Typical age of onset: 40–60 years, but cases are reported in adolescents and the elderly.
  • Gender: Slight male predominance (≈55 % men).

ZES can occur sporadically or as part of the genetic condition multiple endocrine neoplasia type 1 (MEN‑1), which accounts for roughly 20–30 % of cases.[3]

Symptoms

Because excess gastric acid damages the gastrointestinal (GI) lining, symptoms often involve the upper GI tract, but they may also reflect systemic effects of chronic acid loss.

Digestive symptoms

  • Recurrent or refractory peptic ulcers: Often multiple, located beyond the duodenum (e.g., jejunal ulcers).
  • Abdominal pain: Burning or cramping, typically worsening 1–3 hours after meals.
  • Diarrhea: Occurs in 30–50 % of patients; may be fatty (steatorrhea) due to acid‑induced pancreatic enzyme inactivation.
  • Heartburn/GERD: Persistent reflux from acid overload.
  • Nausea & vomiting: Can be triggered by ulcer perforation or severe gastritis.
  • Weight loss: From malabsorption and decreased oral intake due to pain.

Systemic symptoms

  • Fatigue and weakness: Related to anemia from chronic bleeding.
  • Bone pain or fractures: Rarely, chronic acid loss can lead to calcium malabsorption.
  • Kidney stones: Hypercalciuria secondary to altered calcium handling.

Red‑flag symptoms that suggest complications

  • Sudden, severe abdominal pain (possible ulcer perforation).
  • Vomiting of blood or material that looks like “coffee grounds.”
  • Black, tarry stools (melena) indicating GI bleeding.
  • Unexplained fever or chills (possible infection of a perforated ulcer).

Causes and Risk Factors

Pathophysiology

Gastrinomas are neuroendocrine tumors that arise from endocrine cells in the pancreas (most common) or duodenum. The tumor secretes gastrin independent of normal regulatory feedback, leading to:

  1. Parietal cell hyperstimulation → >10‑fold increase in gastric acid.
  2. Acid overwhelms duodenal protective mechanisms → mucosal injury and ulcer formation.
  3. Acid inactivates pancreatic enzymes & bile salts → malabsorption and diarrhea.

Risk factors

  • MEN‑1 syndrome: Inherited mutation of the MEN1 tumor suppressor gene; autosomal dominant.
  • Family history: First‑degree relatives with ZES or MEN‑1 increase risk.
  • Age & sex: Slightly higher risk in men and in individuals >40 years.
  • Chronic atrophic gastritis: Rarely associated; may increase gastrin levels but does not cause gastrinoma.

Diagnosis

Diagnosing ZES requires confirming both hypergastrinemia and acid hypersecretion, then locating the gastrinoma.

Initial laboratory evaluation

  • Fasting serum gastrin: Levels >1000 pg/mL (10× upper limit) are highly suggestive; values >200 pg/mL with low gastric pH are also diagnostic.[4]
  • Gastric pH test: A nasogastric tube aspirate with pH <2 confirms acid hypersecretion.
  • Secretin stimulation test: In ZES, serum gastrin rises >120 pg/mL after an IV bolus of secretin (0.4 U/kg). This test is especially useful when baseline gastrin is only modestly elevated.

Imaging studies to locate the tumor

  1. Endoscopic ultrasound (EUS): High sensitivity (≈85 %) for small pancreatic lesions.
  2. Multiphasic contrast‑enhanced CT scan: Detects tumors >1 cm; assesses liver metastases.
  3. Magnetic Resonance Imaging (MRI) with MRCP: Useful for duodenal lesions and liver lesions.
  4. Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT: Highly sensitive for neuroendocrine tumors, especially metastases.

Additional work‑up

  • Complete blood count (CBC) – assess anemia.
  • Serum calcium, fasting glucose, and IGF‑1 – screen for MEN‑1 associated tumors (parathyroid, pituitary).
  • Upper endoscopy (EGD):* To document ulcer burden and obtain biopsies ruling out H. pylori or malignancy.

Treatment Options

Management combines acid control, tumor removal (when feasible), and long‑term surveillance.

Acid‑blocking therapy (first line)

  • High‑dose proton pump inhibitors (PPIs): Omeprazole 40–80 mg BID, or equivalent. PPIs normalize gastric pH in >90 % of patients and heal ulcers.[5]
  • H2‑receptor antagonists: Only adjunctive; generally insufficient alone for ZES.
  • Therapy is usually life‑long; dose taper is attempted only after sustained symptom‑free period and documented normal gastrin levels.

Surgical management

  • Curative resection: Enucleation or pancreaticoduodenectomy (Whipple) for localized tumors.
  • Debulking surgery: For metastatic disease when complete resection isn’t possible; reduces tumor burden and gastrin output.
  • Operative success depends on tumor size, location, and presence of metastases; 5‑year survival >70 % for localized disease versus ≈30 % for widely metastatic disease.[6]

Medical therapies for unresectable or metastatic disease

  • Somatostatin analogs (octreotide, lanreotide): Inhibit gastrin release; control symptoms in ~50‑60 % of patients.
  • Targeted therapy: Everolimus (mTOR inhibitor) approved for progressive neuroendocrine tumors.
  • Peptide receptor radionuclide therapy (PRRT): ^177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive cells; shows promising disease control.
  • Chemotherapy: Reserved for high‑grade neuroendocrine carcinomas; regimens include streptozocin‑5‑FU or temozolomide‑capecitabine.

Lifestyle and supportive measures

  • Small, frequent meals; avoid foods that exacerbate reflux.
  • Calcium and vitamin D supplementation if malabsorption is present.
  • Vaccinations for hepatitis B and pneumococcus if liver disease develops.

Living with Zollinger‑Ellison Syndrome (Gastrinoma)

Medication adherence

Take PPIs exactly as prescribed. Missing doses can quickly re‑elevate acid output and cause ulcer recurrence.

Monitoring schedule

  • Every 3–6 months: fasting gastrin level, CBC, liver function tests.
  • Annually: imaging (CT/MRI) to assess for tumor growth or metastasis.
  • For MEN‑1 patients: yearly pituitary, parathyroid, and pancreatic hormone panels.

Nutrition tips

  • Consume adequate protein and healthy fats to offset malabsorption.
  • Consider a low‑fat diet if steatorrhea persists.
  • Stay hydrated; electrolyte disturbances (low potassium, magnesium) can result from chronic diarrhea.

Psychosocial support

Living with a rare chronic disease can be stressful. Join patient groups (e.g., Zollinger‑Ellison Support Network) and seek counseling if anxiety about cancer recurrence appears.

Travel and daily activities

Carry a short‑acting PPI (e.g., pantoprazole 40 mg) in case of missed doses. Keep a copy of your diagnosis and medication list for emergency providers.

Prevention

Because most gastrinomas are sporadic, primary prevention is limited. However, risk can be reduced in the following ways:

  • Genetic counseling: Families with MEN‑1 should receive counseling and periodic screening for gastrinomas and other endocrine tumors.
  • Avoid chronic H. pylori infection: Eradication reduces background gastritis, though it does not prevent gastrinoma.
  • Lifestyle: No specific diet prevents gastrinoma, but maintaining a healthy weight and avoiding tobacco may limit ulcer complications.

Complications

If untreated or inadequately controlled, ZES can lead to serious health problems:

  • Perforated peptic ulcer: Can cause peritonitis—a surgical emergency.
  • Upper GI bleeding: May require endoscopic hemostasis or transfusion.
  • Stricture formation: Chronic ulcer healing can narrow the duodenum, causing obstruction.
  • Malabsorption & nutritional deficiencies: Fat‑soluble vitamin (A, D, E, K) deficits, anemia, osteoporosis.
  • Liver metastases: Present in up to 50 % of patients at diagnosis; associated with reduced survival.
  • Electrolyte imbalance: Chronic diarrhea ➜ hypokalemia, metabolic alkalosis.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe abdominal pain that does not improve with medication.
  • Vomiting blood, material that looks like coffee grounds, or passing black/tarry stools.
  • High fever (>38.5 °C/101 °F) with abdominal tenderness.
  • Rapid heart rate (>120 bpm) accompanied by dizziness or fainting.
  • Severe, persistent diarrhea leading to dehydration (dry mouth, dizziness, reduced urine output).
Prompt treatment can prevent life‑threatening complications such as ulcer perforation or massive bleeding.

References

  1. National Institute of Diabetes and Digestive and Kidney Diseases. “Zollinger‑Ellison Syndrome.” 2023.
  2. World Health Organization. “International Classification of Diseases – Neoplasms.” 2022.
  3. American Association of Clinical Endocrinologists. “MEN‑1 Guidelines.” 2022.
  4. Mayo Clinic. “Zollinger‑Ellison syndrome – Diagnosis.” 2024.
  5. Stanford Health Care. “Management of Gastrinomas.” 2023.
  6. Journal of Clinical Oncology. “Outcomes after surgical resection of gastrinomas.” 2021;39(15):1652‑1660.
  7. Cleveland Clinic. “Peptide Receptor Radionuclide Therapy (PRRT).” 2024.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References